查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1544105

胚胎著床前遺傳學診斷（PGD）的全球市場

Preimplantation Genetic Diagnosis (PGD)
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 173 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到2030年，全球胚胎著床前遺傳學診斷（PGD）市場預計將達到1.604億美元

2023年全球胚胎著床前遺傳學診斷（PGD）市場預計為1.149億美元，預計到2030年將達到1.604億美元，2023-2030年分析期間複合年成長率為4.9%。染色體異常是本報告分析的細分市場之一，預計複合年成長率為 4.2%，到分析期結束時將達到 3,360 萬美元。在分析期間，非整倍體部分的複合年成長率估計為 4.5%。

美國市場預估為3,060萬美元，中國預期複合年成長率為7.2%

預計2023年美國胚胎著床前遺傳學診斷（PGD）市場規模將達3,060萬美元。中國作為世界第二大經濟體，預計2030年市場規模將達3,460萬美元，2023-2030年分析期間複合年成長率為7.2%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 2.7% 和 4.3%。在歐洲，德國的複合年成長率預計為 2.9%。

全球胚胎著床前基因診斷 (PGD) 市場 - 主要趨勢和促進因素總結

胚胎著床前遺傳學診斷 (PGD)：保護您的遺傳健康

胚胎著床前遺傳學診斷（PGD）是一種與體外受精（IVF）結合使用的特殊程序，用於在胚胎植入子宮之前篩檢胚胎是否有遺傳異常。這項技術可以讓有遺傳性疾病或染色體異常病史的夫妻降低將其遺傳給後代的風險。 PGD​​ 涉及對發育中胚胎的一個或多個細胞切片檢查，通常在受精後 3 至 5 天進行，然後進行基因分析以檢測特定突變或染色體異常。僅選擇沒有遺傳異常的胚胎進行植入，增加健康懷孕的機會並降低遺傳疾病的風險。 PGD​​對於囊腫纖維化、亨廷頓病和鐮狀細胞性貧血等遺傳性疾病攜帶者的夫婦尤其有價值，因為它為生殖過程提供了額外的安全保障。

科技進步如何改善胚胎著床前遺傳學診斷 (PGD)？

技術進步顯著提高了胚胎著床前遺傳學診斷（PGD）的準確性、可靠性和範圍。次世代定序儀(NGS) 的出現徹底改變了 PGD，能夠對整個基因組進行全面分析，從而能夠更準確地檢測更廣泛的遺傳異常。該技術還減少了基因分析所需的時間，並能夠在 IVF 過程中快速做出決策。更複雜的切片檢查技術的發展，例如第5天胚胎的體外切片檢查，將提高PGD的安全性和有效性，並將對胚胎造成傷害的風險降至最低，同時允許更大、更具代表性的樣本。此外，生物資訊學和資料分析的進步正在增強對遺傳資料的解釋，並為胚胎的遺傳健康提供更準確和詳細的見解。這些技術進步拓寬了PGD的應用範圍，使其成為確保子孫後代遺傳健康的更強力的工具。

胚胎著床前遺傳學診斷（PGD）的主要用途和好處是什麼？

胚胎著床前遺傳學診斷（PGD）可用於各種生殖環境，並具有許多好處，可增加健康懷孕的機會並降低遺傳性疾病的風險。如果父母一方或雙方都是已知基因突變的攜帶者，PGD可以選擇不攜帶該突變的胚胎，從而大大降低將其遺傳給孩子的風險。 PGD​​ 還可以幫助識別染色體異常的胚胎，這些異常不太可能成功懷孕。此外，PGD 對於接受 IVF 的老年女性很有價值，因為它可以篩檢與老齡化相關的染色體異常，例如唐氏症，從而增加健康懷孕的機會。 PGD​​的主要好處是可以降低遺傳疾病的風險，提高試管嬰兒的成功率，讓準父母安心。透過選擇遺傳健康的胚胎，PGD 可以增強生殖過程，並有助於子孫後代的長期健康。

胚胎著床前遺傳學診斷（PGD）市場成長的因素有哪些？

胚胎著床前遺傳學診斷（PGD）市場的成長受到多種因素的推動。遺傳病患病率的不斷上升以及人們對生殖醫學中基因篩檢益處的認知不斷提高是重要的促進因素。此外，提高 PGD 準確性、安全性和可近性的技術進步也推動了市場成長。對 IVF 的需求不斷成長，尤其是老年女性和有遺傳病史的夫婦，進一步推動了 PGD 的採用。此外，擴大遺傳諮詢服務以指導夫妻完成 PGD 過程也有助於市場成長。先進基因檢測技術的日益普及以及對個人化醫療的日益關注正在進一步推動市場發展。這些因素，加上生殖遺傳學領域持續的技術創新，正在推動 PGD 市場的持續成長。

受訪企業範例（46家知名企業）

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings（LabCorp）
  • Natera, Inc.
  • PerkinElmer, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP14183

Global Preimplantation Genetic Diagnosis (PGD) Market to Reach US$160.4 Million by 2030

The global market for Preimplantation Genetic Diagnosis (PGD) estimated at US$114.9 Million in the year 2023, is expected to reach US$160.4 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Chromosomal Abnormalities, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$33.6 Million by the end of the analysis period. Growth in the Aneuploidy segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$30.6 Million While China is Forecast to Grow at 7.2% CAGR

The Preimplantation Genetic Diagnosis (PGD) market in the U.S. is estimated at US$30.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$34.6 Million by the year 2030 trailing a CAGR of 7.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Preimplantation Genetic Diagnosis (PGD) Market - Key Trends and Drivers Summarized

Preimplantation Genetic Diagnosis (PGD): Safeguarding Genetic Health

Preimplantation genetic diagnosis (PGD) is a specialized procedure used in conjunction with in vitro fertilization (IVF) to screen embryos for genetic abnormalities before they are implanted in the uterus. This technique allows couples with a history of genetic disorders or chromosomal abnormalities to reduce the risk of passing these conditions on to their offspring. PGD involves the biopsy of one or more cells from a developing embryo, typically on the third or fifth day after fertilization, followed by genetic analysis to detect specific mutations or chromosomal abnormalities. Only embryos that are free of genetic defects are selected for implantation, increasing the likelihood of a healthy pregnancy and reducing the risk of genetic diseases. PGD is particularly valuable for couples who are carriers of hereditary conditions such as cystic fibrosis, Huntington's disease, or sickle cell anemia, as it provides an additional layer of assurance in the reproductive process.

How Are Technological Advancements Enhancing Preimplantation Genetic Diagnosis (PGD)?

Technological advancements have significantly improved the accuracy, reliability, and scope of preimplantation genetic diagnosis (PGD). The advent of next-generation sequencing (NGS) has revolutionized PGD by allowing comprehensive analysis of the entire genome, enabling the detection of a broader range of genetic abnormalities with greater precision. This technology has also reduced the time required for genetic analysis, allowing for faster decision-making in the IVF process. The development of more sophisticated biopsy techniques, such as trophectoderm biopsy on day five embryos, has increased the safety and effectiveness of PGD, minimizing the risk of harm to the embryo while providing a larger and more representative sample for analysis. Additionally, advances in bioinformatics and data analysis have enhanced the interpretation of genetic data, providing more accurate and detailed insights into the genetic health of embryos. These technological improvements have expanded the applications of PGD, making it a more powerful tool for ensuring the genetic health of future generations.

What Are the Key Applications and Benefits of Preimplantation Genetic Diagnosis (PGD)?

Preimplantation genetic diagnosis (PGD) is used in various reproductive scenarios, offering numerous benefits that enhance the likelihood of a healthy pregnancy and reduce the risk of genetic disorders. In cases where one or both parents are carriers of a known genetic mutation, PGD allows for the selection of embryos that do not carry the mutation, significantly reducing the risk of passing the condition on to the child. PGD is also used in cases of recurrent pregnancy loss, where it helps identify embryos with chromosomal abnormalities that are less likely to result in a successful pregnancy. Additionally, PGD is valuable for older women undergoing IVF, as it can screen for age-related chromosomal abnormalities, such as Down syndrome, improving the chances of a healthy pregnancy. The primary benefits of PGD include its ability to reduce the risk of genetic diseases, increase the success rate of IVF, and provide peace of mind to prospective parents. By allowing for the selection of genetically healthy embryos, PGD enhances the reproductive process and contributes to the long-term health of future generations.

What Factors Are Driving the Growth in the Preimplantation Genetic Diagnosis (PGD) Market?

The growth in the preimplantation genetic diagnosis (PGD) market is driven by several factors. The increasing prevalence of genetic disorders and the growing awareness of the benefits of genetic screening in reproductive health are significant drivers. Technological advancements that improve the accuracy, safety, and accessibility of PGD are also propelling market growth. The rising demand for IVF procedures, particularly among older women and couples with a history of genetic disorders, is further boosting the adoption of PGD. Additionally, the expansion of genetic counseling services, which guide couples through the PGD process, is contributing to market growth. The increasing availability of advanced genetic testing technologies and the growing focus on personalized medicine are further driving the market. These factors, combined with the continuous innovation in reproductive genetics, are driving the sustained growth of the PGD market.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Natera, Inc.
  • PerkinElmer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Preimplantation Genetic Diagnosis (PGD) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Genetic Disease Prevention Drives Market Growth
    • Technological Advancements in Genetic Testing Propel Market Dynamics
    • Increasing Awareness of Reproductive Health and Genetic Disorders Expands Addressable Market
    • Growing Adoption of In-vitro Fertilization (IVF) Techniques Throws the Spotlight on PGD
    • Focus on Reducing Risk of Genetic Disorders Enhances Market Prospects
    • Increasing Number of Fertility Clinics and Genetic Counseling Centers Boosts Market Reach
    • Expansion of Personalized Medicine and Precision Healthcare Sustains Market Growth
    • Rising Demand for Gender Selection and Family Balancing Accelerates Market Dynamics
    • Growing Awareness of Late Maternal Age and Associated Risks Spurs Market Demand
    • Collaborations between Research Institutes and Healthcare Providers Generate Innovation
    • Advancements in Genomic Technologies and Bioinformatics Propel Market Expansion
    • Focus on Ethical and Regulatory Compliance Enhances Market Opportunities
    • Increasing Healthcare Expenditure and Insurance Coverage Expands Market Reach
    • Rising Number of Fertility Treatments and Success Rates Boost Market Prospects
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Chromosomal Abnormalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Chromosomal Abnormalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Aneuploidy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Aneuploidy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for X-linked Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for X-linked Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Single Gene Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Single Gene Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for HLA Typing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for HLA Typing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Gender selection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Gender selection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Other PGD Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 16: World 7-Year Perspective for Other PGD Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 17: World Preimplantation Genetic Diagnosis (PGD) Market Analysis of Annual Sales in US$ for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • JAPAN
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Japan 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • CHINA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 24: China Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 25: China 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • EUROPE
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 28: Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • FRANCE
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 30: France Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 31: France 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • GERMANY
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ITALY
    • TABLE 34: Italy Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Italy 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • UNITED KINGDOM
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 36: UK Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 37: UK 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • SPAIN
    • TABLE 38: Spain Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Spain 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • RUSSIA
    • TABLE 40: Russia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Russia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 42: Rest of Europe Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Rest of Europe 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2024 & 2030
    • TABLE 46: Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • AUSTRALIA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 48: Australia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Australia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • INDIA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 50: India Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: India 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • SOUTH KOREA
    • TABLE 52: South Korea Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 53: South Korea 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Rest of Asia-Pacific 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • LATIN AMERICA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 56: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 57: Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2024 & 2030
    • TABLE 58: Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ARGENTINA
    • TABLE 60: Argentina Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Argentina 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • BRAZIL
    • TABLE 62: Brazil Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Brazil 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • MEXICO
    • TABLE 64: Mexico Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Mexico 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 66: Rest of Latin America Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of Latin America 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • MIDDLE EAST
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 68: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 69: Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2024 & 2030
    • TABLE 70: Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • IRAN
    • TABLE 72: Iran Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Iran 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • ISRAEL
    • TABLE 74: Israel Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Israel 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • SAUDI ARABIA
    • TABLE 76: Saudi Arabia Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Saudi Arabia 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 78: UAE Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UAE 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 80: Rest of Middle East Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Middle East 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030
  • AFRICA
    • Preimplantation Genetic Diagnosis (PGD) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 82: Africa Recent Past, Current & Future Analysis for Preimplantation Genetic Diagnosis (PGD) by Segment - Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Africa 7-Year Perspective for Preimplantation Genetic Diagnosis (PGD) by Segment - Percentage Breakdown of Value Sales for Chromosomal Abnormalities, Aneuploidy, X-linked Diseases, Single Gene Disorders, HLA Typing, Gender selection and Other PGD Tests for the Years 2024 & 2030

IV. COMPETITION